Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients
SARS-CoV-2 infection and the resulting COVID-19 have afflicted millions of people in an ongoing worldwide pandemic. Safe and effective vaccination is needed urgently to protect not only the general population but also vulnerable subjects such as patients with cancer. Currently approved mRNA-based SA...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/6/e002932.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846172967770259456 |
|---|---|
| author | Emanuela Romano Patrick Ott Steve Pascolo |
| author_facet | Emanuela Romano Patrick Ott Steve Pascolo |
| author_sort | Emanuela Romano |
| collection | DOAJ |
| description | SARS-CoV-2 infection and the resulting COVID-19 have afflicted millions of people in an ongoing worldwide pandemic. Safe and effective vaccination is needed urgently to protect not only the general population but also vulnerable subjects such as patients with cancer. Currently approved mRNA-based SARS-CoV-2 vaccines seem suitable for patients with cancer based on their mode of action, efficacy, and favorable safety profile reported in the general population. Here, we provide an overview of mRNA-based vaccines including their safety and efficacy. Extrapolating from insights gained from a different preventable viral infection, we review existing data on immunity against influenza A and B vaccines in patients with cancer. Finally, we discuss COVID-19 vaccination in light of the challenges specific to patients with cancer, such as factors that may hinder protective SARS-CoV-2 immune responses in the context of compromised immunity and the use of immune-suppressive or immune-modulating drugs. |
| format | Article |
| id | doaj-art-8b6d974d24a64609a432866255690ad6 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-8b6d974d24a64609a432866255690ad62024-11-08T19:40:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-06-019610.1136/jitc-2021-002932Implications of mRNA-based SARS-CoV-2 vaccination for cancer patientsEmanuela Romano0Patrick Ott1Steve Pascolo2Medical Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, FranceDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USADepartment of Dermatology, University Hospital of Zürich, Zürich, SwitzerlandSARS-CoV-2 infection and the resulting COVID-19 have afflicted millions of people in an ongoing worldwide pandemic. Safe and effective vaccination is needed urgently to protect not only the general population but also vulnerable subjects such as patients with cancer. Currently approved mRNA-based SARS-CoV-2 vaccines seem suitable for patients with cancer based on their mode of action, efficacy, and favorable safety profile reported in the general population. Here, we provide an overview of mRNA-based vaccines including their safety and efficacy. Extrapolating from insights gained from a different preventable viral infection, we review existing data on immunity against influenza A and B vaccines in patients with cancer. Finally, we discuss COVID-19 vaccination in light of the challenges specific to patients with cancer, such as factors that may hinder protective SARS-CoV-2 immune responses in the context of compromised immunity and the use of immune-suppressive or immune-modulating drugs.https://jitc.bmj.com/content/9/6/e002932.full |
| spellingShingle | Emanuela Romano Patrick Ott Steve Pascolo Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients Journal for ImmunoTherapy of Cancer |
| title | Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients |
| title_full | Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients |
| title_fullStr | Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients |
| title_full_unstemmed | Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients |
| title_short | Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients |
| title_sort | implications of mrna based sars cov 2 vaccination for cancer patients |
| url | https://jitc.bmj.com/content/9/6/e002932.full |
| work_keys_str_mv | AT emanuelaromano implicationsofmrnabasedsarscov2vaccinationforcancerpatients AT patrickott implicationsofmrnabasedsarscov2vaccinationforcancerpatients AT stevepascolo implicationsofmrnabasedsarscov2vaccinationforcancerpatients |